Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mabion SA held a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the development program for MabionCD20, aimed at treating immune thrombocytopenia (ITP). The meeting covered product development strategy, CMC, clinical data, and the regulatory pathway. The company expects the official FDA meet
Mabion SA announced it has held a Pre-IND Type B meeting with the U.S. Food and Drug Administration (FDA) regarding the development of MabionCD20 for the treatment of Immune Thrombocytopenia (ITP).